Medicine and Dentistry
Adenocarcinoma
100%
Colorectal Carcinoma
84%
Overall Survival
81%
Metastatic Colorectal Cancer
78%
Neoplasm
73%
Diseases
44%
Malignant Neoplasm
42%
DNA Mismatch Repair
41%
Microsatellite Instability
40%
Pancreas Adenocarcinoma
33%
Clinical Trial
28%
Progression Free Survival
26%
Surgery
24%
Immunotherapy
24%
Cancer
24%
Metastatic Carcinoma
22%
Recurrent Disease
22%
Immune Checkpoint Inhibitor
20%
Oncology
19%
Pancreas Cancer
19%
Hazard Ratio
18%
Epidermal Growth Factor Receptor
17%
Colorectal Liver Metastasis
17%
Nivolumab
15%
Immunity
15%
Biological Marker
15%
Prognostic Factor
14%
Hepatectomy
14%
Oxaliplatin
14%
Cancer of Unknown Primary Origin
14%
Cytoreductive Surgery
12%
Chemoradiotherapy
12%
Recurrence Free Survival
11%
Systemic Therapy
10%
Adverse Event
10%
Small Intestine
10%
Liver Metastasis
10%
Pembrolizumab
9%
Retrospective Study
9%
Pancreaticoduodenectomy
9%
Odds Ratio
9%
Biopsy Technique
9%
Bevacizumab
9%
Circulating Tumor DNA
9%
Survival Rate
9%
CpG Island
9%
Targeted Therapy
8%
Lymph Node
8%
Programmed Death-Ligand 1
8%
Appendix Tumor
8%
Keyphrases
Metastatic Colorectal Cancer (mCRC)
92%
Colorectal Cancer
59%
Overall Survival
57%
Microsatellite Instability-high (MSI-H)
44%
Small Bowel Adenocarcinoma
30%
Confidence Interval
29%
Tumor
29%
Mismatch Repair
28%
Progression-free Survival
26%
Deficient Mismatch Repair (dMMR)
23%
Pancreatic Ductal Adenocarcinoma
21%
Ampullary Adenocarcinoma
21%
Phase II Study
21%
Chemotherapy
20%
Immune Checkpoint Inhibitors
20%
Appendiceal Adenocarcinoma
19%
Small Intestine
18%
Oxaliplatin
17%
KRAS mutation
17%
Median Overall Survival
17%
Colorectal Liver Metastases
15%
Systemic Chemotherapy
15%
Pancreatic Cancer
14%
Hazard Ratio
14%
Bevacizumab
13%
Nivolumab
13%
Circulating Tumor DNA (ctDNA)
12%
Clinical Trials
12%
Preoperative Therapy
12%
Adenocarcinoma
12%
Hepatectomy
12%
Cancer Patients
11%
5-fluorouracil (5-FU)
10%
Anti-PD-1
10%
Tumor Subtype
10%
Resection
10%
Cancer of Unknown Primary
10%
Immune Checkpoint Blockade
9%
Microsatellite Stable Colorectal Cancer
9%
Capecitabine
9%
Oncology
9%
BRAF mutation
9%
Metastatic Disease
9%
In Cancer
9%
MD Anderson Cancer Center
8%
Surgical Resection
8%
Solid Tumors
8%
Prognostic Factors
8%
Malignancy
8%
Odds Ratio
8%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
82%
Overall Survival
56%
Neoplasm
54%
Colorectal Carcinoma
54%
Chemotherapy
49%
Adenocarcinoma
43%
Malignant Neoplasm
40%
Diseases
36%
Progression Free Survival
27%
Clinical Trial
23%
Epidermal Growth Factor Receptor
23%
Pancreas Cancer
22%
Oxaliplatin
22%
Pancreas Adenocarcinoma
19%
Biological Marker
17%
Bevacizumab
16%
Fluorouracil
14%
Immunotherapy
14%
Adverse Event
13%
Nivolumab
13%
Immune Checkpoint Inhibitor
13%
Circulating Tumor DNA
13%
Irinotecan
11%
Gemcitabine
10%
Paclitaxel
10%
Metastasis
9%
Sodium Fluoride
9%
Recurrent Disease
9%
Colorectal Liver Metastasis
9%
Solid Malignant Neoplasm
9%
Capecitabine
8%
Ipilimumab
8%
Advanced Cancer
8%
Recurrence Free Survival
8%
Randomized Clinical Trial
7%
Pembrolizumab
6%
Combination Therapy
6%
Chemoradiation Therapy
6%
Taxane
6%
Cytokine
6%
Cetuximab
6%
Erlotinib
6%
Colorectal Tumor
6%
Placebo
5%
Carcinoembryonic Antigen
5%
Liver Metastasis
5%
Cisplatin
5%